Podcast 23 Feb 2024 Precision neuromedicine: A new dawn for neurological disorders …to current treatments for neurological and psychiatric diseases. Current treatments often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance and discontinuation. By more precisely targeting… February 23, 2024 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Jan 2025 Singapore’s biotech scene: 7 companies leading the way in 2025 …biomarker for external clinical compounds that has reached the clinical stages. Engine’s biology search platform, called NetMAPPR, maps biological networks and reveals critical genetic and molecular interactions integral to diseases,… January 14, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Jun 2023 Enhancing canine wellness: The promise of immunotherapy for dogs …treat allergic diseases in dogs has been around for several decades now, but there has been a surge of interest and research aimed at harnessing the power of the immune… June 9, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 Jun 2024 Eight companies tackling cancer with allogeneic cell therapy in 2024 …as cancer, cardiovascular diseases, autoimmune disorders, and genetic diseases. The market size was valued at $255.6 million in 2022, and is expected to grow at a compound annual growth rate… June 13, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 24 Jan 2024 A new chapter in cell therapy: engineered B cells reach the clinic for the first time Cell therapy has drastically improved the scope of treatment for a number of diseases in the last few years. Now, engineered B cells are the latest approach in the field… January 24, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 11 Sep 2017 Could a Protein in Yeast hold the Secret to Escaping Age-Related Diseases? …is found in animals and humans too, could help to overcome age-related diseases. During the study, yeast cells were exposed to different stress conditions and lifespan, protein synthesis and Gcn4… September 11, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 25 Apr 2019 European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not? …there still room for more development in this somewhat crowded area? Eric Tauber, CEO of Themis Bioscience, an Austrian biotech that focuses on vaccines for infectious diseases and cancer, believes… April 25, 2019 - 11 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx… August 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022 Prurigo nodularis treatment recommended for EU approval …often co-morbid diseases. These diseases include approved indications for Dupixent, such as atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP), as well as investigational diseases prurigo nodularis and… November 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Aug 2019 Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience …and focused on rare diseases. There are 7,000 rare diseases that affect 60 million people in Europe and the United States, but only 5% have treatments today. These often affect… August 7, 2019 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market? …innings compared to oncology treatments, and it’s primarily targeting rare and orphan diseases. The model for these diseases is very different with pharma.” Frédéric Revah, CEO of Généthon, was more… March 28, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Startup Scout 25 Oct 2019 This UK AI Tool Researches Diseases for Drug Discovery Companies …Healx, which recently raised €51M to fund the development of technology for identifying repurposed drugs for rare diseases. “We really like Healx here at Biorelate and think the company has… October 25, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email